In patients with HF with reduced ejection fraction, the estimated aggregate benefit is maximal for a combination of angiotensin receptor–neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists, and sodium–glucose cotransporter-2 inhibitors [26]. Here, NR3C2 is linked to hydrops fetalis.